NCT05964361CompletedPhase 1/2
First-in-human interleukin-15-transpresenting Wilms’ tumor protein 1-targeting autologous dendritic cell vaccination in cancer patients
Source: EU CTIS (euclinicaltrials.eu) · Last updated 3 Sept 2025
Brief summary (registry, in English)
To evaluate the feasibility and safety of IL-15-transpresenting WT1-targeted DC vaccine production and administration in patients with advanced or refractory solid tumors
- Status (registry)
- Completed
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- First submitted
- 22 Oct 2024
- Start date
- 6 Dec 2023
- Lead sponsor
- Antwerp University Hospital
- Diseases
- Pancreatic cancer, Liver and biliary tract cancer, Gastric and esophageal cancer, Ovarian cancer
- NCT number
- NCT05964361
- EU CT number
- 2024-515296-35-00
- EudraCT number
- 2020-004124-42
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 10
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of any investigational agent within 4 weeks before the planned day of leukapheresis
Other illness
- Active or history of autoimmune disease or immune deficiency
Other
- Pregnancy or breastfeeding
Who the study is looking for
- Diagnosis with a histologically or cytologically confirmed solid tumor of the pancreas, esophagus, liver or ovaries that is advanced, or recurrent or progressing after at least first-line anti-cancer treatment, or for which no alternative standard therapy is available due to intolerance to or refusal of standard-of-care treatment
- At least 1 measurable or evaluable lesion as defined by the latest version of Immune-related Response Evaluation Criteria in Solid Tumors (iRECIST) criteria
- Reasonable life expectancy of at least 3 months (in the Investigator’s opinion)
- Aged ≥ 18 years at the time of signing informed consent
- World Health Organization (WHO) performance status 0-2
- Adequate hematologic and end-organ function
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Antwerp University Hospital Coordinator of this site? Confirm its status | Edegem | Belgium | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.